Bevacizumab (therapeutic anti-VEGF antibodies) is used, in combination with chemotherapy or targeting therapy, to clinically treat colon cancer.41 IL-6 is the key component of the cytokine release syndrome in immunotherapy-induced adverse events, and combination of IL-6 antibody (or IL-6R antibody) is now widely used in CAR-T cell therapy.42 Therefore, these results may provide a theoretical basis suggesting that targeting XBP1 alone might be an alternative strategy to targeting a combination of IL-6 and VEGFA for CRC therapy. Here, XBP1 is linked to colonic neoplasm.